Ellen Johnson

Member of Macroaxis Editorial Board

Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
Company Analysis
ellen@macroaxis.com

Ellen Johnson Latest Stories - Published

CTRN
  8 hours ago at Macroaxis 
By Ellen Johnson
It seems Citi Trends may not have a good chance to recover from the latest slide as its shares fell again. The company current daily volatility is 3.38 percent, with a beta of 1.49 and an alpha of -0.05 over DOW. As some institutional investors are moving away from the latest market volatility rise, we are going to outline Citi Trends based on how it reacts to economic swings. I will address the reasons why this entity does not get much respect from institutional investors under the current market uncertainty.
QDEL
  a day ago at Macroaxis 
By Ellen Johnson
It appears without question that Quidel Cp will continue to recover much faster as its share price surged up 9.99% today. The company current daily volatility is 3.54 percent, with a beta of -1.78 and an alpha of 0.27 over DOW. While some baby boomers are getting worried about quidel cp, it is reasonable to summarize Quidel Cp. What exactly are Quidel Cp shareholders getting in December?
NVGS
  a day ago at Macroaxis 
By Ellen Johnson
The reasoning behind this post is to give retail investors our take on Navigator future value. We will discuss the reasons why it could be a game-changer for Navigator Holdings retail investors.
CVAC
  a day ago at Macroaxis 
By Ellen Johnson
The next fiscal year end is expected on the 26th of April 2022. Although many conservative investors are getting more into healthcare space, we should study Curevac NV's current fundamentals in more details. We will look into reasons why it is still very possible for the company to generate above-average returns. Curevac NV current chance of bankruptcy is under 24 percent. Will investors continue to be optimistic, or should we expect a sell-off?
MDWT
  a day ago at Macroaxis 
By Ellen Johnson
Midwest Holding Book Value per Share is comparatively stable at the moment as compared to the past year. Midwest Holding reported Book Value per Share of 31.75 in 2020. Debt to Equity Ratio is likely to gain to 7.65 in 2021, whereas Free Cash Flow is likely to drop (16.7 M) in 2021. As some conservative investors are getting more into financial services space, Midwest Holding could be a your radar. I will take a closer look at this stock and the newest sentiment generated by private investors. In this post, I will also go over a few different drivers affecting Midwest Holding's products and services, and explain how it may impact Midwest Holding private investors.
GLUE
  2 days ago at Macroaxis 
By Ellen Johnson
As many rational traders are trying to avoid healthcare space, it makes sense to digest Monte Rosa Therapeutics a little further and understand how it stands against Mustang Bio and other similar entities. We are going to discuss some of the competitive aspects of both Monte and Mustang.
HLTH
  2 days ago at Macroaxis 
By Ellen Johnson
The next fiscal quarter end is expected on the 31st of December 2021. The stock goes through an active upward rally. As many retail investors are getting excited about healthcare space, it is fair to concentrate on Cue Health outlook under the current economic conditions. I will address why stockholders ignored this entity since the beginning of the current economic outlook.
CYCN
  3 days ago at Macroaxis 
By Ellen Johnson
Cyclerion Therapeutics Net Cash Flow from Investing is quite stable at the moment as compared to the past year. The company's current value of Net Cash Flow from Investing is estimated at 19,421.05. Share Based Compensation is expected to rise to about 15.3 M this year, although the value of Average Assets will most likely fall to about 111.2 M. In this post, we will outline Cyclerion Therapeutics. We will evaluate if Cyclerion Therapeutics shares are reasonably priced going into December. In this post, I will also go over some essential variables affecting Cyclerion Therapeutics' products, and show how it may impact Cyclerion Therapeutics outlook for active traders this year.
GAME
  few days ago at Macroaxis 
By Ellen Johnson
The upcoming quarterly report is expected on the 29th of November 2021. The stock experiences an active upward rally. Engine Gaming Enterprise Value over EBIT is projected to slightly grow based on the last few years of reporting. The past year's Enterprise Value over EBIT was at 6.30. The current year Enterprise Value over EBITDA is expected to grow to 6.41, whereas Price to Book Value is forecasted to decline to 5.01. While some of us are becoming more enthusiastic about entertainment space, let's digest Engine Gaming And in greater detail to make a better estimate of its debt utilization. Let's try to discuss if Engine Gaming shares are reasonably priced going into December.
DRMA
  few days ago at Macroaxis 
By Ellen Johnson
While many traders are getting carried away by overanalyzing healthcare space, it is reasonable to go over Dermata Therapeutics. We will check if it is still possible for Dermata Therapeutics to minimize net losses this year. This post is to show some fundamental factors affecting Dermata Therapeutics' products and services. I will also drop some light on how it may impact the investing outlook for the company in December.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Thematic Ideas
Explore Investing Ideas